KTTA — Pasithea Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1841330 ·
Last close
$0.43
Market Cap
$14.51M
52W High
$2.06
52W Low
$0.28
ADV30
1,275,894
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,713,282 | -5,273,852 | 51,709,945 | 45,663,782 | 1,870,258 |
| Mar 2026 | 0 | — | -4,876,644 | -2,869,482 | 56,354,901 | 50,400,377 | 1,542,451 |
| Dec 2025 | 0 | — | -10,256,162 | -10,110,868 | 60,240,070 | 55,158,939 | 5,020,832 |
| Sep 2025 | 0 | — | -3,110,055 | -3,037,420 | 13,630,664 | 4,122,953 | 1,423,982 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,781,583
Investing CF
—
Financing CF
$56,314,691
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-78,153,795
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-23,956,143
Pretax Income TTM
$-21,291,622
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,857,295 | -20,427,683 | 60,240,070 | 5,020,832 | 55,219,238 | -15,211,490 |
| Dec 2024 | 0 | -14,249,962 | -13,904,584 | 16,064,719 | 1,282,043 | 14,782,676 | -13,923,438 |
| Dec 2023 | 0 | -15,979,361 | -15,961,658 | 26,116,858 | 2,718,406 | 23,398,452 | -13,425,411 |
| Dec 2022 | 0 | -12,588,971 | -13,936,452 | 45,180,089 | 2,681,841 | 42,498,248 | -13,691,158 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$5,153,685
NetIncome TTM
$-21,291,622
OpCashFlow TTM
—
Assets (Latest)
$51,709,945
Forward EPS
$-0.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MCRB | Seres Therapeutics, Inc. | $14.37M | $1.41 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $14.73M | $5.65 | — |
| MDNAF | Medicenna Therapeutics Corp. | $14.77M | $0.16 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $14.24M | $0.52 | — |
| INTI | Inhibitor Therapeutics, Inc. | $13.98M | $0.08 | — |
News headlines (Yahoo Finance, 1h cache)
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 Eur
2026-11-13 07:00 · Yahoo
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
2026-11-03 12:00 · Yahoo
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
2026-10-28 20:05 · Yahoo
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
2026-10-23 13:15 · Yahoo
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
2026-04-20 11:01 · Yahoo
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?
2026-05-03 12:59 · Yahoo
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
2026-06-15 11:02 · Yahoo
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-06-10 13:55 · Yahoo
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
2026-05-04 11:01 · Yahoo
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
2026-04-01 11:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.